News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
The provider of integrated clinical development analytics products and services this month appointed a new chief commercial officer, Otis Johnson, PhD, MPA.
In this position, Johnson will be responsible for growing Phesi’s offerings, focusing on the commercialization of ClinSite, the company’s recently launched, AI-driven clinical trial investigator site selection tool.
Johnson spent 13 years at Merck in various roles before transitioning to the contract research side, first as the vice president of clinical research at Syneos and then as a vice president at Icon.
“My intention is to make Phesi’s technology and clinical trial services available for routine use in clinical studies in all therapeutic areas,” Johnson told us. “I plan on expanding our customer base by providing biotech and pharmaceutical companies, and CROs access to our vast, automated clinical trial database and AI technology to improve their operations by 25-40%.”
Speaking to the development of ClinSite, Johnson added, “The pharmaceutical industry has struggled to incorporate newer technologies, such as machine learning, into routine clinical development deliverables. This is the case because of poor or incomplete data to train the models. Phesi has developed a predictive algorithm that works despite these typical issues with data sources.”